Axogen (AXGN) closed at $37.46 on October 27, 2026, down 1.5% from the previous close, on volume of 1,750,473 shares (30-day average 1,313,662).
Data as of October 27, 2026.
27-Oct-2026
Here are the major earnings before the open Wednesday
Seeking Alpha News (Tue, 27-Oct 6:00 PM ET)
AxoGen Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 27-Oct 1:57 PM ET)
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Globe Newswire (Wed, 14-Oct 7:00 AM ET)
Wound Care Stocks Are Posting Double-Digit Growth. Here's Why.
Globe Newswire (Tue, 6-Oct 9:06 AM ET)
Globe Newswire (Thu, 1-Oct 5:19 PM ET)
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Globe Newswire (Thu, 10-Sep 6:01 AM ET)
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Globe Newswire (Thu, 10-Sep 6:00 AM ET)
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
Globe Newswire (Tue, 11-Aug 3:35 PM ET)
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Axogen trades on the NASDAQ stock market under the symbol AXGN.
As of October 27, 2026, AXGN stock price declined to $37.46 with 1,750,473 million shares trading.
AXGN has a beta of 1.18, meaning it tends to be more sensitive to market movements. AXGN has a correlation of 0.06 to the broad based SPY ETF.
AXGN has a market cap of $2.20 billion. This is considered a Mid Cap stock.
Last quarter Axogen reported $70 million in Revenue and $.12 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.03.
In the last 3 years, AXGN traded as high as $52.91 and as low as $3.45.
The top ETF exchange traded funds that AXGN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
AXGN has outperformed the market in the last year with a price return of +106.2% while the SPY ETF gained +14.8%. However, in the short term, AXGN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -5.1% vs +4.4% return in SPY. But in the last 2 weeks, AXGN shares have fared better than the market returning +0.9% compared to SPY -1.1%.
AXGN support price is $36.99 and resistance is $39.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AXGN shares will trade within this expected range on the day.